<?xml version="1.0" encoding="UTF-8"?>
<funding-group>
 <award-group id="award001">
  <funding-source>
   <institution-wrap>
    <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100010666</institution-id>
    <institution>H2020 Research Infrastructures</institution>
   </institution-wrap>
  </funding-source>
  <award-id>731060</award-id>
  <principal-award-recipient>
   <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6890-0820</contrib-id>
   <name>
    <surname>Failloux</surname>
    <given-names>Anna-Bella</given-names>
   </name>
  </principal-award-recipient>
 </award-group>
 <funding-statement>This study was funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 731060 (Infravec2, Research Infrastructures for the control of vector-borne diseases; 
  <ext-link ext-link-type="uri" xlink:href="http://infravec2.eu/" xmlns:xlink="http://www.w3.org/1999/xlink">http://infravec2.eu/</ext-link>). CB was supported by the Institut Pasteur. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 </funding-statement>
</funding-group>
